vivosim-logo
  • Technology
    • NAMkind™ Liver Model
    • NAMkind™ Intestine Model
  • Services
    • Liver Toxicology Services
    • Gastrointestinal Toxicology Services
    • Investigational Toxicology Services
    • Liver Efficacy Services
    • Gastrointestinal Efficacy Services
  • Company
    • About
    • Leadership
    • Board of Directors
    • Distributors
    • Conferences & Events
    • Publications
  • Investors
    • Overview
    • Stock Quote & Chart
      • Historical Stock Quote
      • Investment Calendar
    • Press Releases
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Leadership Team
      • Board of Directors
      • Committee Composition
    • Investor Alerts
    • Investor Contacts
    • Investor Presentations
  • Customer Portal
  • Contact
Publications

Identification of JAK Inhibitors as Potential Therapeutics for Inflammatory Bowel Disease Using Human Primary Cell 3D Models of Crohn’s Disease and Ulcerative Colitis

Publications

Development of a Multicellular 3D Intestinal Model Using Human Primary Cells to Identify Novel IBD Therapies

Publications

Clinically Benchmarked Multi-Endpoint 3D Liver Spheroid NAM for DILI Prediction and SAR Prioritization 

Publications

Human 3D Liver Spheroid NAM for ADC DILI Risk Assessment 

Publications

A Machine-Learning Enhanced Human Intestinal NAM for Diarrhea Risk Assessment Across Small Molecules and ADCs  

Publications

Multicellular Human 3D Liver NAM for DILI Risk Assessment Across Small Molecules and Antibody Drug Conjugates 

Publications

Multicellular Human Intestinal NAM for Diarrhea Risk Stratification Across Small Molecules and Antibody Drug Conjugates

Publications

NAMkind™ Liver & Intestine Toxicity Prediction Across Small Molecules and Antibody Drug Conjugates 

Publications

NAMkind™ Client Study Report

Publications

Identify GI risk. Advance with insight.

For more information or to schedule an inquiry

Click Here
vivsim logo

© VivoSim Labs, Inc. 2026

logo
  • Technology
    • NAMkind™ Liver Model
    • NAMkind™ Intestine Model
  • Services
    • Liver Toxicology Services
    • Gastrointestinal Toxicology Services
    • Investigational Toxicology Services
    • Liver Efficacy Services
    • Gastrointestinal Efficacy Services
  • Company
    • About
    • Leadership
    • Board of Directors
    • Distributors
    • Conferences & Events
    • Publications
  • Investors
    • Overview
    • Stock Quote & Chart
      • Historical Stock Quote
      • Investment Calendar
    • Press Releases
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Leadership Team
      • Board of Directors
      • Committee Composition
    • Investor Alerts
    • Investor Contacts
    • Investor Presentations
  • Customer Portal
  • Contact